Gilead Sciences had a strong quarter with revenue growth and bottom-line growth. They showcased promising data from the PURPOSE 1 trial for HIV prevention. The imminent launch of seladelpar and progress in oncology positions them well for the future.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing